Clinical experience of human leucocyte interferon in the management of herpetic keratitis

D. J. Coster, M. G. Falcon, K. Cantell, B. R. Jones

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A series of 78 patients was admitted to the trial. All the ulcers healed within 48 hours, the majority in 24 hours. In the placebo group 49 per cent developed focal recurrences. Of those receiving the low dose interferon (11 x 106 unit/ml) 30 per cent developed lesions, and in the high dose group (33 x 106 unit/ml) 20 per cent showed evidence of viral activity. The difference between the recurrence rate in the placebo groups and the interferon high dose groups is not likely to have occurred by chance, for a χ2 test gives a P value of <0.05. Careful examination of the external eye failed to reveal any evidence of untoward reaction to the drug, nor did any patient develop stromal disease. It is too early to assess any effect on recurrence rates.

Original languageEnglish
Pages (from-to)327-329
Number of pages3
JournalTransactions of the Ophthalmological Societies of the United Kingdom
Volume97
Issue number2
Publication statusPublished - 1 Jan 1977
Externally publishedYes

Fingerprint Dive into the research topics of 'Clinical experience of human leucocyte interferon in the management of herpetic keratitis'. Together they form a unique fingerprint.

  • Cite this